Adverse Drug Reactions

Center for Molecular Medicine First Midwest-Based Lab Offering Roche Test to Help Predict Drug Performance & Improve Safety

Published in Medical Letter on the CDC and FDA, July 1st, 2007

The Center for Molecular Medicine (CMM) announced it is the first Midwest-based laboratory to offer the FDA-approved AmpliChip(R) CYP450 Test to physicians and hospitals.

This genomics-based, FDA-approved clinical laboratory test provides physicians information that may be used to help determine a patient's unique ability or inability to metabolize a large variety of prescription drugs. AmpliChip CYP450 test results may be used by physicians to make more rational drug prescription decisions, reduce "trial and error" prescription and dosing and guard against dangerous and expensive adverse drug reactions.

Reports from the Institute of Medicine and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-07-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry